Literature DB >> 33732196

The Impact of Matching to Psychotherapy Preference on Engagement in a Randomized Controlled Trial for Patients With Advanced Cancer.

Allison Marziliano1, Allison Applebaum2, Anne Moyer3, Hayley Pessin2, Barry Rosenfeld4, William Breitbart2.   

Abstract

Objective: This study examined whether patients who were randomly assigned to their preferred therapy arm had stronger engagement with their treatment than those who were randomly assigned to a non-preferred therapy arm. Method: Data were drawn from a RCT comparing Individual Meaning-Centered Psychotherapy (IMCP), with Individual Supportive Psychotherapy (ISP), in patients with advanced cancer. Treatment engagement was operationalized as patients' perceptions of the therapeutic alliance with their therapist and therapy sessions attended. Two 2 by 2 Analysis of Variance (ANOVA) models were used, with treatment preference (IMCP vs. ISP) and treatment assignment (IMCP vs. ISP) as the independent variables and working alliance and number of sessions attended as outcome variables.
Results: Patients who preferred and were assigned to IMCP reported a significantly stronger alliance than those who preferred IMCP but were assigned to ISP. Conclusions: The findings from this study have broader implications for research on psychotherapy beyond the appeal of IMCP in advanced cancer patients. Patients who prefer a novel psychotherapy that they cannot engage in elsewhere, but receive the standard treatment may experience weaker alliance than patients who prefer the standard but receive the novel therapy. Trial registration: Clinicaltrial.gov ID: NCT01323309.
Copyright © 2021 Marziliano, Applebaum, Moyer, Pessin, Rosenfeld and Breitbart.

Entities:  

Keywords:  alliance; attrition; engagement; matching; patient preferences

Year:  2021        PMID: 33732196      PMCID: PMC7959844          DOI: 10.3389/fpsyg.2021.637519

Source DB:  PubMed          Journal:  Front Psychol        ISSN: 1664-1078


  25 in total

1.  THE WORKING ALLIANCE AND THE TRANSFERENCE NEUROSIS.

Authors:  R R GREENSON
Journal:  Psychoanal Q       Date:  1965-04

2.  Factors associated with attrition from a randomized controlled trial of meaning-centered group psychotherapy for patients with advanced cancer.

Authors:  Allison J Applebaum; Wendy G Lichtenthal; Hayley A Pessin; Julia N Radomski; N Simay Gökbayrak; Aviva M Katz; Barry Rosenfeld; William Breitbart
Journal:  Psychooncology       Date:  2011-07-12       Impact factor: 3.894

3.  The impact of client treatment preferences on outcome: a meta-analysis.

Authors:  Joshua K Swift; Jennifer L Callahan
Journal:  J Clin Psychol       Date:  2009-04

4.  Rapid screening for psychologic distress in men with prostate carcinoma: a pilot study.

Authors:  A J Roth; A B Kornblith; L Batel-Copel; E Peabody; H I Scher; J C Holland
Journal:  Cancer       Date:  1998-05-15       Impact factor: 6.860

Review 5.  Defining empirically supported therapies.

Authors:  D L Chambless; S D Hollon
Journal:  J Consult Clin Psychol       Date:  1998-02

6.  Therapy processes, progress, and outcomes for 2 therapies for gynecological cancer patients.

Authors:  Sharon L Manne; Shannon Myers-Virtue; Deborah A Kashy; Melissa Ozga; David Kissane; Carolyn Heckman; Mark Morgan
Journal:  Psychooncology       Date:  2016-12-22       Impact factor: 3.894

7.  Patients' preferences and randomised trials.

Authors:  C Bradley
Journal:  Lancet       Date:  1996-04-20       Impact factor: 79.321

8.  Therapeutic alliance and obesity management in primary care - a cross-sectional pilot using the Working Alliance Inventory.

Authors:  E A Sturgiss; G M Sargent; E Haesler; E Rieger; K Douglas
Journal:  Clin Obes       Date:  2016-11-09

9.  Randomized versus historical controls for clinical trials.

Authors:  H Sacks; T C Chalmers; H Smith
Journal:  Am J Med       Date:  1982-02       Impact factor: 4.965

10.  Information needs of patients with cancer: results from a large study in UK cancer centres.

Authors:  V Jenkins; L Fallowfield; J Saul
Journal:  Br J Cancer       Date:  2001-01-05       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.